

# Open End PERLES on Rogers International Commodity Platinum Excess Return Index



## Final Terms

### Product Details

Underlying Index	<b>Rogers International Commodity Platinum Excess Return Index</b> (Bloomberg: RICIPLER)	
Issue Amount	20'000 Open End PERLES (with reopening clause)	
Conversion	1 Open End PERLES refers to the level of one Underlying Index	
Reference Level of Underlying Index	958.35	
Issue Price	USD 958.35 (100% of Reference Level of Underlying Index)	
Security No./ codes	ISIN: CH0024450949 <b>Valor: 2 445 094</b>	WKN: UB141K Common Code:

### Dates

Issue Date	10 February 2006
Pricing Date	10 February 2006
Payment Date	17 February 2006
Expiration Date	Open End

### General Information

Issuer	UBS AG, London Branch (Rating Aa2 / AA+)
Lead Manager	UBS AG, Zurich (UBS Investment Bank)
Calculation Agent	UBS AG, London Branch
Settlement	Cash Settlement in USD
Exchange Business Day	A day at which the Underlying Index is calculated and published with the Index Sponsor.
Exchange(s)	The stock exchanges on which components comprising the Underlying Index are traded, as determined by the Index Sponsor from time to time.
Index Sponsor	Diapason Commodities Management SA
Trading	Indicative Prices will be available on Reuters UBSDEEW05 and <a href="http://www.ubs.com/keyinvest">www.ubs.com/keyinvest</a> from 9:00 to 17:30 CET
Clearing	SIS, Euroclear, Clearstream (booked at SIS SegalInterSettle AG)
Listing	No listing
Issuer Call Right	The Issuer has the annual right, on 17 February, for the first time on 17 February 2007 ("Notice Date"), to call the Open End Certificates for early redemption, at the value of the current Underlying Index level, effective 1 year after "Notice Date" has been published to that effect (in case that any of the dates is not a business day, the next following business day applies)
Investor Exercise Right	In addition to the possibility to sell the Open End Certificates at any time, each Investor has an annual right to exercise their Open End Certificates for the value of the current Underlying Index level. The notice has to be received not later than 10 am on 17 February. The Exercise will become effective as of close of business on 17 February of the relevant year (in case that this day is not a business day, the next following business day applies).

#### UBS Investment Bank is a business group of UBS AG

This document is for your information only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any financial product. The information and opinions contained in this document have been compiled from or arrived at in good faith from sources believed to be reliable. No representation or warranty, express or implied as to the accuracy or completeness or the information contained herein is made by UBS AG. All opinions expressed herein are subject to change without notice. Futures and Options trading is considered risky, and past performance is not necessarily indicative for future results. Additional note to persons receiving this document in Italy: Any Italian persons receiving this document and requiring further information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan.

This document is not intended for distribution into the USA, to U.S. Persons.

#### Contact:

UBS AG, P.O. Box, 8098 Zurich

Institutional Investors: Zurich: +41-44-239 68 00\*  
Geneva: +41-22-389 50 05\*  
Private Investors: 0848-911-011\*  
E-Mail: [derivatives@ubs.com](mailto:derivatives@ubs.com)  
Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.



Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and should not be construed as an offer, recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the product (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This term sheet shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in the Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

## Selling Restrictions

Any Product purchased by any person for resale may not be offered in any jurisdiction in circumstances, which would result in the Issuer being obliged to register any further prospectus or corresponding document relating to the Product in such jurisdiction.

**Holders of this Product are advised to read the selling restrictions described more fully in the relevant Terms and Conditions of this Product. The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Holders of this Product should seek specific advice before on-selling it.**

**Hong Kong** - This Product has not been offered and sold, and each purchaser represents and agrees that it will not offer and sell the Product in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy and sell shares or debentures, whether as principal or agent, or in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) of Hong Kong or to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance, or in other circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance. In relation to the issue of this Product, each purchaser represents and agrees that it has not issued and will not issue any advertisement, invitation or document relating to the Product, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Product which is or is intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance and any rules made thereunder.

**Luxembourg** – The Terms and Conditions related to this product have not been approved by and will not be submitted for approval to the competent authority in Luxembourg - the Commission de Surveillance du Secteur Financier (CSSF) - and consequently are not authorized for public offering in Luxembourg. The Term Sheet or other marketing material may therefore not be distributed and the product not be offered in Luxembourg other than (1) to legal entities which are authorized or regulated to operate in the financial markets or if not so authorized / regulated, whose corporate purpose is solely to invest in securities, or to other Qualified Investors in the meaning of the Luxembourg Law on prospectuses for securities of 10 July 2005, (2) to persons who invest in the product for a minimum sum of 50.000 EUR for each investment or (3) to up to 100 persons not qualified as a Qualified Investors in the above-mentioned sense.

**Singapore** - *The following applies subsequent to the coming into force of the amendments to Part XIII of the SFA (as amended by the Securities and Futures (Amendment) Act 2005).*

This Term Sheet has not been registered as a prospectus with the Monetary Authority of Singapore under the Securities and Futures Act (Cap. 289) of Singapore ("SFA"). Accordingly, this Term Sheet and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the bonds/securities may not be circulated or distributed, nor may the bonds/securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor specified in Section 274 of the SFA, (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

In the event where the bonds/securities are subscribed or purchased under Section 275 by a relevant person which is:

- (a) a corporation (which is not an accredited investor) the sole business of which is to hold investment and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
- (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor;

then the shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest in that trust shall not be transferable for six months after that corporation or that trust has acquired the bonds/securities under Section 275 except:

- (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA;
- (2) where no consideration is given for the transfer; or
- (3) by operation of law.

**UK** – This Product should not be sold with a consideration of less than €50,000 or equivalent.

**USA** – This Product may not be sold or offered within the United States or to U.S. persons, the foregoing shall not, however, prohibit sales to U.S. offices of UBS AG.

### UBS Investment Bank is a business group of UBS AG

This document is for your information only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any financial product. The information and opinions contained in this document have been compiled from or arrived at in good faith from sources believed to be reliable. No representation or warranty, express or implied as to the accuracy or completeness or the information contained herein is made by UBS AG. All opinions expressed herein are subject to change without notice. Futures and Options trading is considered risky, and past performance is not necessarily indicative for future results. Additional note to persons receiving this document in Italy: Any Italian persons receiving this document and requiring further information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan.

This document is not intended for distribution into the USA, to U.S. Persons.

**Contact:** UBS AG, P.O. Box, 8098 Zurich

**Institutional Investors:** Zurich: +41-44-239 68 00\*  
Geneva: +41-22-389 50 05\*

**Private Investors:** 0848-911-011\*

**E-Mail:** derivatives@ubs.com

**Internet:** www.ubs.com/keyinvest

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

## Index Disclaimer

This product is not sponsored, endorsed, sold or promoted by Diapason Commodities Management SA ("Diapason"), or by Beeland Interests, Inc. or Jim Rogers (collectively, "Beeland"). Neither Beeland nor Diapason makes any representation or warranty, express or implied, or accepts any responsibility, regarding the accuracy or completeness of any materials describing this product or the results to be obtained from purchasing this product, or the advisability of investing in securities or commodities generally, or in futures or in this product particularly.

## Final Terms and Conditions / Prospectus:

The prospectus of the security described in this termsheet can be ordered under Tel. 044 / 239 47 03, Fax 044 / 239 21 11 or via E-Mail: [swiss-prospectus@ubs.com](mailto:swiss-prospectus@ubs.com) or from your client advisor.

### UBS Investment Bank is a business group of UBS AG

This document is for your information only and is not intended to be an offer, or a solicitation of an offer, to buy or sell any financial product. The information and opinions contained in this document have been compiled from or arrived at in good faith from sources believed to be reliable. No representation or warranty, express or implied as to the accuracy or completeness or the information contained herein is made by UBS AG. All opinions expressed herein are subject to change without notice. Futures and Options trading is considered risky, and past performance is not necessarily indicative for future results. Additional note to persons receiving this document in Italy: Any Italian persons receiving this document and requiring further information should contact Giubergia UBS SIM SpA, an affiliate of UBS SA, in Milan.

This document is not intended for distribution into the USA, to U.S. Persons.

**Contact:** UBS AG, P.O. Box, 8098 Zurich

**Institutional Investors:** Zurich: +41-44-239 68 00\*  
Geneva: +41-22-389 50 05\*  
**Private Investors:** 0848-911-011\*  
**E-Mail:** [derivatives@ubs.com](mailto:derivatives@ubs.com)  
**Internet:** [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

Please note that calls made to the numbers marked with an asterisk (\*) may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.